Indivior and Reckitt sued for blocking generics of opioid drug Suboxone
Indivior (LSE: INDV) and Reckitt Benckiser (LSE: RB) face legal action in the USA for allegedly abusing its monopoly to keep generic versions of the opioid addiction drug Suboxone (buprenorphine and naloxone) off the market.
UK-based Indivior, which was spun out from Reckitt Benckiser in 2014, is being sued by the office of New York Attorney General Eric Schneiderman, 34 other states and the District of Columbia.
The lawsuit alleges that Reckitt and Indivior tried to coerce patients to switch from a tablet to a dissolvable oral strip version of Suboxone, and engaged in other anticompetitive business practices to maintain its monopoly over the drug, which is used to treat patients addicted to heroin and other drugs, including painkillers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze